MAT2B

Across TCGA pan-cancer cohorts, MAT2B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MAT2B data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MAT2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAT2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD and UCEC are the cancer types where MAT2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.211	0.709	.015	3	view →
UCEC	DFS	Median	All	0.899	0.617	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MAT2B–STAD (DFS)

Open the STAD breakdown →